Passa al contenuto
Merck
Tutte le immagini(3)

Key Documents

453R-2

Sigma-Aldrich

p53 (EP9) Rabbit Monoclonal Primary Antibody

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

rabbit

Livello qualitativo

100
500

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

EP9, monoclonal

Descrizione

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

Confezionamento

vial of 0.1 mL concentrate (453R-24)
vial of 0.1 mL concentrate Research Use Only (453R-24-RUO)
vial of 0.5 mL concentrate (453R-25)
bottle of 1.0 mL predilute ready-to-use (453R-27)
vial of 1.0 mL concentrate (453R-26)
vial of 1.0 mL concentrate Research Use Only (453R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (453R-27-RUO)
bottle of 7.0 mL predilute ready-to-use (453R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (453R-28-RUO)

Produttore/marchio commerciale

Cell Marque™

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:200 (concentrate)

Controllo

breast carcinoma ((breast ductal carcinoma in-situ)), colorectal carcinoma, ovarian carcinoma ((ovarian serous carcinoma)), urothelial carcinoma

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Visualizzazione

nuclear

Informazioni sul gene

human ... TP53(7157)

Categorie correlate

Descrizione generale

Anti-p53 tumor suppressor protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53, although significant accumulation of the mutant form of p53 protein due to longer half-life is the basis for the test using the IHC technique. Nuclear staining with this antibody has been shown in breast carcinoma, lung carcinoma, colorectal carcinoma, and urothelial carcinoma.

Qualità

United States - IVD
Canada - IVD
European Union - IVD
Japan - RUO

Linkage

p53 Positive Control Slides, Product No. 453S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Stato fisico

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota sulla preparazione

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot

Altre note

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Note legali

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

12 - Non Combustible Liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

David J Dabbs et al.
The American journal of surgical pathology, 37(7), e1-11 (2013-06-14)
Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are
J K McKenney et al.
The American journal of surgical pathology, 25(8), 1074-1078 (2001-07-28)
Distinction of urothelial carcinoma in situ (CIS) from reactive atypia on the basis of morphology alone may be difficult in some cases. Because this distinction is therapeutically and prognostically critical, we attempted to determine if an immunohistochemical panel would help
C Midulla et al.
Anticancer research, 19(5B), 4033-4037 (2000-01-11)
The different clinical evolution of breast cancer with similar pathological characteristics prompted the authors to investigate the prognostic significance of different biological markers. Seventy-one primary breast carcinoma specimens obtained by mastectomy or quadrantectomy were examined for the determination of the
F A Mauri et al.
International journal of oncology, 15(6), 1137-1147 (1999-11-24)
Steroid receptor analysis is the only widely accepted prognostic/predictive marker in breast cancer (BC) treatment. In the present study we evaluated the prognostic role of ER/PgR with p53 and Bcl2, in a series of 277 BC (153 pN1/2, 122 pNO
D C Quinlan et al.
Cancer research, 52(17), 4828-4831 (1992-09-01)
Mutations in the gene coding for the p53 tumor suppressor protein are common in a variety of human cancers. To assess the role of a putative mutated p53 protein in human lung cancer, a monoclonal antibody recognizing it was used
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.